SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Livepeer project aims to deliver a live video streaming network protocol that is fully decentralized, highly scalable, crypto token incentivized, and results in a solution which can serve as the live media layer in the decentralized development (web3) stack. In addition, Livepeer is meant to provide an economically efficient alternative to centralized broadcasting solutions for any existing broadcaster. In this document we describe the Livepeer Protocol - a delegated stake based protocol for incentivizing participants in a live video broadcast network in a game-theoretically secure way. We present solutions for the scalable verification of decentralized work, as well as the prevention of useless work in an attempt to game the token allocations in an inflationary system.  The Livepeer Token (LPT) is the protocol token of the Livepeer network. But it is not the medium of exchange token. Broadcasters use Ethereum's Ether (ETH) to broadcast video on the network. Nodes who contribute processing and bandwidth earn ETH in the form of fees from broadcasters. LPT is a staking token that participants who want to perform work on the network stake in order to coordinate how work gets distributed on the network, and to provide security that the work will get done honestly and correctly. LPT has the following purposes:  It serves as a bonding mechanism in a delegated proof of stake system, in which stake is delegated towards transcoders (or validators) who participate in the protocol to transcode video and validate work. The token, and potential slashing that occurs due to protocol violation, is necessary in order to secure the network against a number of attacks. More below. It routes work through the network in proportion to the amount of staked and delegated token, essentially serving as a coordination mechanism.  It is a unit of account that is specific to the Livepeer ecosystem, which forms the basis of a SectorCoin concept, applicable to additional functionality to be introduced in the future. Services such as DVR, closed captioning, ad insertion/monetization, and analytics can all plug into the Livepeer ecosystem and potentially make use of the security provided by staking LPT.  An initial allocation of Livepeer Token will be distributed so that stakeholders can fulfill various roles in, and use the network, and then additional token will be issued according to algorithmically programmed issuance over time.  Following the conventions of Ethereum and many popular ERC20 tokens, LPT will be divisible by 10 ^ 18, with larger denominations such as the LPT itself intended to be used for user level transactions such as staking, and smaller denominations intended to be used for protocol accounting.

Livepeer Token

Livepeer (LPT) is actively discussed amid significant trading volume, driven by community excitement around its role in decentralized video infrastructure and potential integration with generative AI, including SORA AI. Investors are highlighting attractive staking opportunities and its trending status as key factors, positioning LPT as a notable AI-focused cryptocurrency.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma (formerly Cybin Inc.) is trending following its recent rebrand and NASDAQ listing under the symbolic ticker $HELP, signaling a strategic shift towards late-stage clinical development in mental health. While some investors see this as a pivotal move to enhance visibility and believe the company is undervalued compared to its psychedelic sector peers, others express skepticism, viewing the rebranding as superficial given past stock performance and concerns about dilution. The community is actively debating the implications of this transition and eagerly awaiting upcoming clinical data for its HLP003 and HLP004 programs.

Toyota Motor Corp. engages in the manufacture and sale of motor vehicles and parts. It operates through the following segments: Automotive, Financial Services, and All Other. The Automotive segment designs, manufactures, assembles and sells passenger cars, minivans, trucks, and related vehicle parts and accessories. It is also involved in the development of intelligent transport systems. The Financial Services segment offers purchase or lease financing to Toyota vehicle dealers and customers. It also provides retail leasing through lease contracts purchased by dealers. The All Others segment deals with the design, manufacture, and sale of housing, telecommunications and other businesses. The company was founded by Kiichiro Toyoda on August 28, 1937 and is headquartered in Toyota, Japan.

Toyota Motor Corporation - ADR

Toyota Motor Corp.

Toyota is trending as investors monitor evolving US-Japan tariff discussions, which significantly influence its import costs and production strategies. This comes amid a notable corporate development concerning its potential buyout of Toyota Industries, met with activist investor scrutiny. The community is also keenly observing Toyota's strategic advancements in autonomous driving through a recent Waymo partnership, while evaluating its strong hybrid sales growth against broader industry shifts and EV market challenges.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community emphasizes a steadfast commitment to "Bongterm" growth and positive culture, contrasting it with short-term hype. Discussions highlight the token's role within the evolving global cannabis movement and the anticipation of policy shifts impacting the sector. Members proudly position Weedcoin on Solana as a symbol of decentralized health and cultural sovereignty.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is heavily trending ahead of its highly anticipated 3-year topline data release for ELEVIDYS from the EMBARK study, scheduled for an upcoming Monday morning conference call. Community discussion is sharply divided, with many speculating positive results could ignite a significant price surge or a potential buyout, while others remain cautious, citing past disappointments and the persistent influence of short sellers.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares ($FBIOP) are trending as the community eagerly anticipates the sale of a Priority Review Voucher (PRV) awarded to its subsidiary, Cyprium Therapeutics, following a recent drug approval. This significant cash infusion, alongside strong sales for Journey Medical's Emrosi and the expected Unloxcyt launch, is driving discussions about potential dividend reinstatement for preferred shareholders and the stock's perceived undervaluation.

BlackRock Institutional Trust Company N.A. - iShares Gold Trust

iShares Gold Trust

iShares Gold Trust ($IAU) is witnessing substantial investor interest, fueled by escalating global geopolitical tensions, persistent inflation concerns, and a strong community perception of gold as a vital safe haven asset. Investors are actively discussing its role as a hedge against potential currency devaluation, further underscored by reports of ongoing central bank accumulation.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed as it recently finalized the strategic acquisition of Astria Therapeutics, bolstering its hereditary angioedema (HAE) pipeline and securing improved financing terms. While the company reported strong revenue performance and a significant ORLADEYO price increase, the community is navigating cautious forward guidance that has led to mixed investor sentiment and concerns about market manipulation. Despite these dynamics, many perceive BCRX as undervalued, anticipating a potential re-rating as its strengthened portfolio and profitability trajectory evolve.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics (UNCY) is trending as a recent 13G filing confirmed Millennium Management's significant ownership stake, signaling growing institutional interest. This institutional activity coincides with high community anticipation for the FDA's acceptance of the company's New Drug Application resubmission for Oxylanthanum Carbonate (OLC). Investors are optimistic about OLC's potential approval and the assignment of a PDUFA date, as the prior Complete Response Letter was related to manufacturing compliance, not the drug's efficacy.

Packaging Corporation of America engages in the production of container products. It operates through the following segments: Packaging, Paper, and Corporate and Other. The Packaging segment offers a variety of corrugated packaging products, such as conventional shipping containers. The Paper segment manufactures and sells a range of papers, including communication-based papers, and pressure sensitive papers. The Corporate and Other segment focuses on transportation assets, such as rail cars, and trucks. The company was founded in 1959 and is headquartered in Lake Forest, IL.

Packaging Corp Of America

Packaging Corp of America is actively discussed as the market evaluates its recent earnings miss and a cautious outlook, prompting a stock decline. Community sentiment is weighing the long-term benefits of the Greif acquisition against immediate challenges from soft industrial demand and rising input costs. This creates a contentious debate around the cyclical health of the packaging sector, with some anticipating further headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings...

Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average...

Fred Aslan Sells 6,375 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...

HC Wainwright Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock

HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday...

Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus...

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Equity

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.


Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

ARTV
Artiva Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARTV News

ARTVArtiva Biotherapeutics Inc